Vismederi
Vismederi is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants
Sponsor Osivax
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
Randomized, Observer-blind, Active-controlled, Phase 3 Study in Adults ≥60 Years of Age to Assess the Safety and Immunogenicity of Abbott’s Candidate High-dose Influenza Vaccine
Sponsor Abbott Biologicals B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years
Sponsor Osivax
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.
Sponsor Seqirus UK Limited
- Start (EU)
- Latest update
- Estimated end
Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
Sponsor University Of Antwerp
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2, randomized, dose-finding/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Vismederi?
The 2026-10-09 snapshot links Vismederi to 10 distinct CTIS trials. Recorded services include Laboratory services, Lab testing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Vismederi?
The most frequently recorded therapeutic areas are Infectious Disease, Respiratory. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Vismederi conducted?
The linked trials record locations in 9 countries, including Belgium, Germany, Finland, Estonia, Spain. These are trial locations, not confirmed office locations or countries where Vismederi delivered services.
What can this page tell me about Vismederi's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Vismederi. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Vismederi S.r.l.